Post-Marketing Surveillance of Gliadel 7.7mg Implant (All-case Observational Study)
Post-marketing surveillance to investigate the clinical safety and effectiveness in patients of all implantation of Gliadel with malignant glioma in the actual medical setting.
Malignant Glioma
OTHER: No intervention
Number of Adverse Events/Serious Adverse Events, Up to 3 months
Survival rate, Survival rate of subjects measured up to 1 year after implantation of Gliadel, Up to 1 year
Post-marketing surveillance to investigate the clinical safety and effectiveness in patients of all implantation of Gliadel with malignant glioma in the actual medical setting.